NASDAQ:FOLD - Amicus Therapeutics Stock Price, News, & Analysis

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced its quarterly earnings results on Monday, November, 5th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by $0.04. The biopharmaceutical company earned $20.60 million during the quarter, compared to analysts' expectations of $23.56 million. Amicus Therapeutics had a negative return on equity of 52.03% and a negative net margin of 463.82%. The business's revenue was up 89.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.41) EPS. View Amicus Therapeutics' Earnings History.

Amicus Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Amicus Therapeutics.

Amicus Therapeutics issued an update on its FY 2018 earnings guidance on Monday, November, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $80-90 million, compared to the consensus revenue estimate of $89.85 million.

5 analysts have issued 1-year target prices for Amicus Therapeutics' stock. Their forecasts range from $12.00 to $31.00. On average, they expect Amicus Therapeutics' stock price to reach $20.40 in the next twelve months. This suggests a possible upside of 89.2% from the stock's current price. View Analyst Price Targets for Amicus Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amicus Therapeutics.

Headlines about FOLD stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amicus Therapeutics earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days.

Amicus Therapeutics saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 26,372,583 shares, an increase of 0.9% from the October 15th total of 26,141,775 shares. Based on an average daily volume of 2,764,033 shares, the short-interest ratio is currently 9.5 days. Approximately 14.4% of the shares of the company are sold short. View Amicus Therapeutics' Current Options Chain.

Some companies that are related to Amicus Therapeutics include Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Beigene (BGNE), Amarin (AMRN), SAGE Therapeutics (SAGE), Amneal Pharmaceuticals (AMRX), Nektar Therapeutics (NKTR), Alkermes (ALKS), Dr.Reddy's Laboratories (RDY), Catalent (CTLT), GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), United Therapeutics (UTHR), HUTCHISON CHINA/S (HCM) and GW Pharmaceuticals PLC- (GWPH).

Amicus Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.65%), FMR LLC (7.11%), Jennison Associates LLC (5.32%), Janus Henderson Group PLC (4.65%), Victory Capital Management Inc. (1.98%) and Franklin Resources Inc. (1.85%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Life Sciences Maste Perceptive, Margaret G Mcglynn, Michael Raab, Perceptive Advisors Llc and William D Baird III. View Institutional Ownership Trends for Amicus Therapeutics.

FOLD stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Allianz Asset Management GmbH, Russell Investments Group Ltd., Jennison Associates LLC, Rhumbline Advisers, FMR LLC, Fox Run Management L.L.C. and Bank of New York Mellon Corp. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Donald J Hayden Jr, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Margaret G Mcglynn, Michael Raab and William D Baird III. View Insider Buying and Selling for Amicus Therapeutics.

FOLD stock was purchased by a variety of institutional investors in the last quarter, including Rothschild & Co. Asset Management US Inc., AXA, Janus Henderson Group PLC, Pictet Asset Management Ltd., Fosun International Ltd, BlackRock Inc., Canada Pension Plan Investment Board and Dimensional Fund Advisors LP. Company insiders that have bought Amicus Therapeutics stock in the last two years include John F Crowley, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for Amicus Therapeutics.

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of FOLD stock can currently be purchased for approximately $10.78.

Amicus Therapeutics has a market capitalization of $2.00 billion and generates $36.93 million in revenue each year. The biopharmaceutical company earns $-284,000,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Amicus Therapeutics employs 325 workers across the globe.

The official website for Amicus Therapeutics is http://www.amicusrx.com.

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]